Frontier technology, unparalleled.
Product: Nexstim NBS
Nexstim Navigated Brain Therapy (NBT) uses SmartFocus® transcranial magnetic stimulation to precisely localise and accurately modulate the surface of the brain associated with medication-resistant major depressive disorder. By reliably locating and targeting the exact same area of the dorso-lateral prefrontal cortex per session, Nexstim NBT systems are capable of delivering the highest possible reproducibility of TMS therapy possible.
E-field navigated stimulation enables accurate targeting of the dorsolateral prefrontal cortex (DLPFC) without anatomic assumptions.
Non-navigated TMS hits the DLFPC in just 30% of cases vs 100% reported in Nexstim Smartfocus rnTMS.
Precise and personalised dosing over multiple treatment sessions, emphasising the current direction for optimal results.
TGA, FDA and CE-marked for treatment of medication resistant major depressive disorder. Preliminary applications for pain and neurologic rehabilitation.
Conventional protocols for rTMS (10Hz bursts of 40 pulses, one burst every 30s) and Theta burst protocols for rTMS (50Hz burst of 3 pulses).
Precise navigation data is stored according to the individual and targeted each session.
Nexstim's e-field enables optimised delivery of therapeutic doses at the DLPFC.
The patient remains comfortable and the magnetic coil stable throughout the session.
"What makes this so special is the ability for it to define very small, precise cortical regions on the surface of the brain, and define individual components of function, which is something we never could do before"
Neuroclast is a proud business and collaborative partner with Nexstim to introduce navigated transcranial navigation to the Australian and New Zealand markets.
nTMS is currently being outsourced by Neuroclast in Melbourne, AUS.
Please inquire if you would like to refer a patient, or arrange a demonstration.
We have designed and instituted a multi-centre trial for nTMS in supratentorial brain tumour surgery to explore the impact it can have on surgical planning, clinical outcomes, and direct cortical stimulation findings.
What is Navigated TMS?
Transcranial magnetic stimulation (TMS) introduced in 1985.
Initially developed as a research tool, integration with stereotactic neuro-imaging rendered it a prospective clinical tool.
Line navigation was insufficient for precise targeting of neural function.
Nexstim was the first, and only, medical device company to localise the coil's true electric field (E-field) relative to the brain.
Partnered with MRI neuro-imaging En-TMS is the most accurate and precise product in the world for presurgical mapping and therapeutic applications.
Nexstim's accuracy and clinical efficacy is supported by peer-reviewed medical research.
An electromagnetic field can be created that generates an electrical field at the surface of the scalp. There are various types of "coils" that can induce different stimulation effects on the human brain. Traditionally, TMS is stimulated with an approximate understanding of anatomic targets.
Stereotactic imaging uses a three-dimensional coordinate system for anatomical targeting, compared to other imaging modalities which are 2D. This makes targeting more effective, especially if you're trying to localise eloquent cortical regions that have important implications for treatment.
Line navigation refers to how the TMS system's coils align with the imaging relative to the scalp. Given that TMS coils are often bulky, it is difficult to partner stereotaxy with these coils.
This is critically important when making treatment-related decisions inferred from TMS data. Nexstim's SMART FOCUS technology is novel and patented, and contributes to the most accurate, precise and reproducible electrical field possible.
In the context of neurosurgery, accuracy of non-invasive mapping such as En-TMS is crucial. Nexstim's NBS and NBT systems use the SMART FOCUS technology to ensure that data is accurate and can be exported in DICOM format into all intraoperative navigation systems.
Over 100 peer-reviewed papers involving 4,000+ patients have been published throughout the U.S, EU and U.K as of 2020. Neuroclast is establishing formal research partnerships with tertiary and non-tertiary hospitals using the NBS and NBT systems.
Contact Neuroclast for an inspection or demonstration of the NBS or NBT system today.